A novel ambidentate type hydroxamic acid derivative (phenhaH, 1) containing an (O,O) and a 1,10-phenantroline (phen) based (N,N) donoratom set together with its heterobimetallic complexes incorporating an octahedral [Co(4 N)]³⁺ (4 N = tris(2-aminoethyl)amine (tren) or tris(2-methylpyridyl)amine (tpa)) and a half-sandwich type [(η⁶-p-cym)Ru]²⁺ entity have been synthesized and characterized using various analytical techniques. Reaction of [Co(4 N)Cl]Cl₂ with 1 proved the exclusive (O,O) coordination of the ligand to the [Co(4 N)]³⁺ core to yield [Co(tpa)(phenha)](ClO₄)₂, (2). Subsequent treatment of 1 with [Ru(η⁶-p-cym)Cl₂]₂ and [Co(4 N)Cl]Cl₂ in a one-pot reaction resulted in the formation of [(η⁶-p-cym)Ru(Cl)(phenha)Co(tren)]Cl(PF₆)₂ (3) and [(η⁶-p-cym)Ru(Cl)(phenha)Co(tpa)](PF₆)₃ (4) in which the organometallic Ru core is coordinated by the phen part while the Co entity by the hydroxamate part of 1. Cyclic voltammetry revealed that 4 could be reduced at a less negative potential and exhibits a reversible Co(III)/Co(II) redox process compared to 3 due to the π-back bonding interaction between the Co(III) centre and the pyridyl-N donors of tpa in 4. Complexes 2–4 were tested for their in vitro cytotoxicity using human-derived cancer cell lines (HeLa, MCF-7, HCT116 and MDA-MB-231) and showed moderate anti-proliferative activity in the double digit micromolar concentration range, 4 being the most active. Complex 4 displayed better activity against MDA-MB-231 cells than cisplatin.

一种新型的双齿型异羟肟酸衍生物（phenhaH，1），其中包含基于（O，O）和1,10-菲咯啉（phen）的（N，N）供体原子，以及包含八面体[Co（4 N ）] ³⁺（4 N =三（2-氨基乙基）胺（TREN）或三（2-甲基吡啶基）胺（TPA））和半夹心型[（η ⁶ - p -cym）的Ru] ²⁺实体已经使用各种分析技术对它们进行了合成和表征。[Co（4 N）Cl] Cl ₂与1的反应证明了配体与[Co（4 N）] ³⁺核的排他（O，O）配位，产生[Co（tpa）（phenha）] ClO ₄）₂，（2）。后续处理的1用的[Ru（η ⁶ - p -cym）氯₂ ] ₂和[CO（4 N）CL]氯₂在一个单釜反应导致的形成[（η ⁶ - p -cym）的Ru（Cl）的（phenha）的Co（TREN）]氯（PF ₆）₂（3）和[（η ⁶ - p -cym）的Ru（Cl）的（phenha）的Co（TPA）]（PF ₆）₃（4 ），其中有机金属Ru核由phen部分配位，而Co实体由1的异羟肟酸酯部分配位。循环伏安法显示4由于3的Co（III）中心与tpa的吡啶基-N供体之间的π背键相互作用，与3相比较，可以在较低的负电位下还原并表现出可逆的Co（III）/ Co（II）氧化还原过程。4。配合物2 - 4测试它们测试在体外使用人衍生的癌细胞系（HeLa细胞，MCF-7，HCT116和MDA-MB-231）的细胞毒性和在两位数微摩尔浓度范围内表现出中等的抗增殖活性，4感最活跃。复合物4显示出比顺铂更好的针对MDA-MB-231细胞的活性。